Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
37.74
+2.94 (+8.45%)
Streaming Delayed Price
Updated: 9:54 AM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Unveiling 8 Analyst Insights On Corcept Therapeutics
↗
July 30, 2024
Via
Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
July 29, 2024
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
6 Analysts Have This To Say About Corcept Therapeutics
↗
June 17, 2024
Via
Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
↗
May 31, 2024
NASDAQ:CORT is showing good growth, while it is not too expensive.
Via
Chartmill
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
May 29, 2024
Via
Benzinga
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
↗
July 15, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
↗
July 15, 2024
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.
Via
Chartmill
7 Biotech Stocks to Boost Your Portfolio to Peak Health
↗
June 26, 2024
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
Via
InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
↗
June 26, 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.
Via
InvestorPlace
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
June 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
↗
May 09, 2024
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.
Via
Chartmill
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
↗
May 02, 2024
Via
Benzinga
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
↗
June 24, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is showing good growth, while it is not too expensive.
Via
Chartmill
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
↗
June 14, 2024
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly...
Via
Benzinga
Topics
Lawsuit
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 14, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 03, 2024
Via
Benzinga
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
June 03, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
May 28, 2024
Via
Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
May 28, 2024
Via
Benzinga
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
↗
May 28, 2024
Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant improvements in hypertension and hyperglycemia.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 28, 2024
Via
Benzinga
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
May 28, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
↗
May 10, 2024
Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 09, 2024
Via
Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 01, 2024
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
